Protocol #: 17-380
Status
Recruiting
Description
This research study is studying a combination of drugs as a possible treatment for BRAF-mutant melanoma. The drugs involved in this study are: - Itacitinib (INCB039110) - Dabrafenib - Trametinib
Condition
Melanoma
Interventions
Trametinib
Dabrafenib
INCB039110
Phase
Phase 1
Study Type
Interventional
Further Study Details
Primary Outcome:
Maximum Tolerated Dose
Secondary Outcome:
Objective Response Rate
Progression Free Survival
Overall Survival
Complete response rate
Partial Response Rate
Stable Disease
Progressive Disease
Estimated Enrollment
38
Study Start Date
May 29, 2019
Eligibility
Gender: All
Minimum Age: 18 Years
Maximum Age: N/A
Health Volunteers: No
Criteria
Massachusetts General Hospital
Information Provided By
Massachusetts General Hospital
Official Title
Phase I Study of INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.
Clinicaltrials.gov Identifier
NCT03272464

 

 

Source: Clinicaltrials.gov. Through our founding membership in the Dana-Farber/Harvard Cancer Center, an NCI-designated Comprehensive Cancer Center, these clinical trials are conducted at the Massachusetts General Hospital Cancer Center and may be available at other partner institutions.

Back to Top